NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.80 -0.02 (-1.10%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Cardiol Therapeutics Stock (NASDAQ:CRDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.75▼$1.8650-Day Range$1.78▼$2.4852-Week Range$0.72▼$3.12Volume281,941 shsAverage Volume416,681 shsMarket Capitalization$143.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingBuy Company OverviewCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Cardiol Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 692nd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 39.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 39.56%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.03 News SentimentCardiol Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Cardiol Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Stock News HeadlinesQ3 EPS Estimate for Cardiol Therapeutics Cut by AnalystOctober 30 at 1:17 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL)October 28 at 3:43 AM | americanbankingnews.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 31, 2024 | Weiss Ratings (Ad)Cardiol Therapeutics’ Strategic Advancements Boost Market Potential and Revenue ProjectionsOctober 24, 2024 | markets.businessinsider.comCardiol Therapeutics (CRDL) Gets a Buy from Roth MKMOctober 24, 2024 | markets.businessinsider.comAre Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?October 22, 2024 | msn.comCardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trialOctober 22, 2024 | proactiveinvestors.comWholesale inflation remained cool last month in latest sign that price pressures are slowingOctober 12, 2024 | ca.finance.yahoo.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $0.8432 at the beginning of 2024. Since then, CRDL shares have increased by 113.5% and is now trading at $1.80. View the best growth stocks for 2024 here. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. Who are Cardiol Therapeutics' major shareholders? Top institutional shareholders of Cardiol Therapeutics include Lion Street Advisors LLC (0.40%), Foundations Investment Advisors LLC (0.23%) and Wealth Enhancement Advisory Services LLC (0.02%). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/12/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CUSIPN/A CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.75 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+386.1%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.65% Return on Assets-85.28% Debt Debt-to-Equity Ratio0.01 Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual Sales$60,000.00 Price / Sales2,387.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book5.63Miscellaneous Outstanding Shares79,585,000Free Float66,213,000Market Cap$143.25 million OptionableNot Optionable Beta0.89 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:CRDL) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.